215309-00-5

Usage

Chemical Properties

White to brown powder

Upstream product

• 204078-31-9 3-(morpholin-4-yl)benzonitrile 
• 145127-37-3 ethyl 3-(morpholin-4-yl)benzoate 
• 110-91-8 morpholine 
• 535-80-8 3-chlorobenzoate 
• 403-54-3 m-Fluorobenzonitrile 
• 221876-08-0 N-(3-morpholinobenzoyl)morpholine 
• 451-02-5 ethyl 3-fluorobenzoate 
• 24398-88-7 ethyl 3-bromobenzoate 
• 6952-59-6 3-cyanobromobenzene 

Downstream Products

• 221876-07-9 3-morpholinobenzoyl chloride 
• 1616960-88-3 N-(2-(2-methyl-1H-indol-1-yl)ethyl)-3-morpholinobenzamide 
• 1394161-92-2 5-(3-morpholinophenyl)oxazole-4-carboxylic acid 
• 1394161-91-1 methyl 5-(3-morpholinophenyl)oxazole-4-carboxylate 
• 1383341-15-8 3-(4-morpholinyl)-N-[1-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]benzamide 
• 1000895-68-0 N-methoxy-N-methyl-3-morpholin-4-yl-benzamide 
• 911433-72-2 3-morpholin-4-yl-N-[3-({2-[(3-morpholin-4-ylpropyl)amino]pyrimidin-5-yl}ethynyl)phenyl]benzamide 
• 911434-14-5 N-[5-[2-(2-aminopyrimidin-5-yl)ethynyl]pyridin-3-yl]-3-morpholin-4-yl-benzamide 
• 258502-85-1 N-[5-(3-dimethylaminobenzamido)-2-methylphenyl]quinoline-6-carboxamide 
• 250681-56-2 N-[2-methyl-5-(3-morpholinobenzamido)phenyl]-4-benzyloxybenzamide 

Relevant academic research and scientific papers

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)

Formation of dispersed palladium-nickel bimetallic nanoparticles in microemulsions: Synthesis, characterization, and their use as efficient heterogeneous recyclable catalysts for the amination reactions of aryl chlorides under mild conditions

A simple method for preparing spherical palladium-nickel bimetallic nanoparticles with a molar ratio of 1.0 (Pd0.5-Ni0.5 B-NPs) has been adopted using a water-in-oil microemulsion system of water/aerosol-OT/ isooctane at room temperature. The morphology, size, structure, and elemental composition of these particles as the superior catalyst were characterized by field emission scanning electron microscopy (FESEM), transmission electron microscopy (TEM), X-ray diffraction (XRD), energy dispersive analysis using X-rays (EDAX), and X-ray fluorescence (XRF) analyses. The effects of the reaction parameters on the Buchwald-Hartwig amination reaction yield in the presence of these NPs as catalyst have been screened and the results are evaluated by using chlorobenzene and morpholine as a model reaction. Initially, differences in the catalytic properties of some synthesized NPs have been compared. In this context, Pd-Ni B-NPs with the molar ratio of 1 : 1 (Pd/Ni = 1) showed the highest catalytic activity for this reaction. The Pd0.5-Ni0.5 B-NPs are stable and the leaching of catalyst in solution is very low. Therefore, they has been employed as efficient catalysts in the C-N coupling reaction. Finally, a mechanism for an amination reaction on the Pd/Ni catalyst surface was proposed.

PYRIMIDINE DERIVATIVES

The invention concerns pyrimidine derivatives of Formula (I) wherein m is 0-3 and each Ris a group such as hydroxy, halogeno, trifluoromethyl and cyano; Ris hydrogen, halogeno or (1-6C)alkyl; n is 0-2 and each Ris a group such as hydroxy, halogeno, trifluoromethyl and cyano; p is 0-4; and Qis aryl or heteroaryl; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

AMIDE DERIVATIVES

The invention concerns amide derivatives of Formula (Ia) wherein X is -NHCO- or -CONH-; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group

Substituted anilino-quinazoline (or quinoline) compounds and use thereof

The invention concerns amide derivatives of Formula (I), wherein: G is N or CH; R1is a group such as hydroxy, halo, trifluoromethyl, C1-6alkyl and C1-6alkoxy; each of R2and R3is hydrogen, halo, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R4is a group such as hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy and C3-7cycloalkyl, or R4is of the Formula (IC): —K—J, wherein J is aryl, heteroaryl or heterocyclyl and K is a bond or a group such as oxy and imino, R5is a group such as hydrogen, halo and trifluoromethyl: m is 1-3 and q is 0-4; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

BEZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES

The invention concerns the use of amide derivatives of formula (I) wherein: R1 and R2 are substituents such as hydroxy, C1-6alkoxy, mercapto, C1-6alkylthio, amino, C1-6alkylamino and di-(C1-6alkyl)amino; m and p are independently 0-3; R3 is C1-4alkyl; q is 0-4; and R4 is aryl or cycloalkyl; or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by cytokines

Benzamide derivatives for the treatment of diseases mediated by cytokines

The invention concerns amide derivatives of Formula (I) wherein: R1and R2include hydroxy, C1-6alkoxy, mercapto, C1-6akylthio, amino and heterocyclyl; m and p are independently 0-3; R3is halo, cyano or C1-6alkoxy; q is 0-4; and R4is aryl or cycloalkyl wherein R4is optionally substituted with up to 3 substituents having any value defined for each R1group; or a pharmaceutically-acceptable salt or in-vivo-cleavable ester thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

Amide derivatives for the treatment of diseases mediated by cytokines

The invention concerns the use of amide derivatives of formula (I) wherein: R1and R2are substituents such as hydroxy, C1-6alkoxy, mercapto, C1-6alkylthio, amino, C1-6alkylamino and di-(C1-6alkyl)amino; m and p are independently 0-3R3is C1-4alkyl; q is 0-4; and R4is aryl or cycloalkyl; or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by cytokines

Amide derivatives useful as inhibitors of the production of cytokines

The invention concerns amide derivatives of formula (I) wherein R3is (1-6C)alkyl or halogeno; Q1is heteroaryl which is optionally substituted with 1, 2, 3, or 4 substituents such as hydroxy, halogeno, trifluoromethyl, (1-6C)alkyl, (1-6C)alkoxy, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, hydroxy-(2-6C)alkoxy, amino-(2-6C)alkylamino, N-(1-6C)alkyl-(1-6C)alkylamino-(2-6C)alkylamino, aryl, heteroaryl and heterocyclyl; p is 0-2 and R2is a substituent such as hydroxy and halogeno; q is 0-4; and Q2includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceutically-acceptable salts or in vivo-cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.